PALO
ALTO, Calif., Sept. 17,
2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
a broad spectrum of retinal diseases, announced today that it will
host an Investor R&D Day with financial analysts and
institutional investors on Monday, September
23, 2024, in New York City
from 10:30 am ET to 12:30 pm ET.
The event will feature presentations and roundtable discussions
on Kodiak's science of durability, science of the enhanced
formulation, timeline and other updates for the Company's active
clinical pipeline, and the Company's expanding Antibody Biopolymer
Conjugate Drug ("ABCD") platform technology.
"We look forward to addressing the most common questions we've
received from investors about Kodiak today and sharing how we
believe our learnings, our course corrections, and our rapid
execution will help us move forward," said Victor Perlroth, M.D., Chief Executive Officer
of Kodiak Sciences.
"Specifically, we will be presenting for the first-time key
pieces of the story of our ABC Platform and of the journey of
Kodiak Sciences: the true science of durability underlying our
platform, including new data demonstrating what we believe is the
longest human ocular half-life achieved by an intravitreal biologic
to date; the science of our enhanced formulation for tarcocimab and
KSI-501, which we believe will provide strong immediacy and
preserve our 6-month predominant durability profile while enabling
a faster and more dispersive dosing and administration for the
benefit of clinicians and patients," continued Victor Perlroth, M.D., Chief Executive Officer
of Kodiak Sciences.
"We will also share deep learnings from tarcocimab's extensive
clinical experience, how we have applied these learnings into our
new clinical studies, and how these improved studies have been
optimized for success. In addition, we will provide updates to
expected timelines for our ongoing clinical trials."
"We also look forward to sharing new progress from our duet and
triplet programs which are built from our Antibody Biopolymer
Conjugate Drug, or ABCD Platform. These pipeline programs have high
drug-to-antibody ratio ("DAR"), are multi-specific and allow us to
modulate biological pathways in new and important ways," continued
Dr. Perlroth.
"As the theme of the presentation, we want to walk you through
our journey which is an evolution from data, to insights, to
educated actions. We encourage the audience to lean in, follow
Kodiak's story and ask questions. We will do our best to address
them together with Wall Street analysts and investors," concluded
Dr. Perlroth.
Featured Speakers
Speakers will include members of the executive team and the
following leading retina specialist key opinion leaders (KOLs):
- David Brown, MD, Clinical
Professor of Ophthalmology, Baylor College of
Medicine; Director of Research, Retina Consultants of
Texas, Houston, TX; Chair, Medical Leadership Board,
Retina Consultants of America
- Charles Wykoff, MD, PhD,
Clinical Professor of Ophthalmology Weill Cornell Medical College,
Houston Methodist Hospital; Clinical Professor of Ophthalmology,
Blanton Eye Institute; Director of Research, Retina Consultants of
Texas; Deputy Chair of
Ophthalmology, Blanton Eye Institute
Investor R&D Day Agenda
The Investor R&D Day agenda will include:
- An overview of how Kodiak has applied recent key learnings to
the clinical development plans of its three clinical programs
- Addressing common questions of investors and highlighting
Kodiak's solutions
- New science of durability data underlying Kodiak's Antibody
Biopolymer Conjugate ("ABC") Platform, including first-time
presentation of human ocular half-life data of tarcocimab, our lead
investigational medicine
- New science of the enhanced formulation for our ABC
investigational medicines tarcocimab and KSI-501, including
analyses and insights that demonstrate how our enhanced
formulations are designed to provide strong immediacy and preserve
our 6-month predominant durability profile while enabling a faster
and more dispersive dosing and administration for the benefit of
clinicians and patients
- An update on our late-stage clinical programs including new
details and rationale on our pivotal trial designs and why we have
high aspirations for the success of these trials
- An overview of the unmet needs in the retinal vascular and
inflammatory disease landscape today and how Kodiak's clinical
programs are designed to address them
- The latest progress on our Antibody Biopolymer Conjugate
Drug ("ABCD") Platform, an evolution of our in-clinic ABC Platform
which has broad therapeutic potential
- Roundtable discussions with Dr. David
Brown and Dr. Charles Wykoff moderated by Dr.
Victor Perlroth, Chief Executive
Officer and Chairman of Kodiak
- Q&A sessions with the audience
In-person attendees are invited to join Kodiak management and
the participating KOLs for additional Q&A over a lunch
reception to conclude the event.
Webcast Information
Kodiak will host a live webcast of the event beginning at 10:30
a.m. ET on Monday, September 23,
2024. To access the webcast, please register
at https://edge.media-server.com/mmc/p/2ff5vrm7.
The live webcast of the event will be available on the "Events
and Presentations" section of Kodiak's Investors & Media
website at http://ir.kodiak.com/. A replay of the webcast will
be available for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical
company committed to researching, developing, and commercializing
transformative therapeutics to treat a broad spectrum of retinal
diseases. We are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABC Platform™
uses molecular engineering to merge the fields of protein-based and
chemistry-based therapies and has been at the core of Kodiak's
discovery engine. We are developing a portfolio of three clinical
programs, two of which are late-stage today and derived from our
ABC Platform and one which is platform-independent and which we
believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases including
diabetic retinopathy, the leading cause of blindness in working-age
patients in the developed world, and wet age-related macular
degeneration, the leading cause of blindness in elderly patients in
the developed world. Tarcocimab is currently being studied in two
Phase 3 clinical trials, GLOW2 in patients with diabetic
retinopathy and DAYBREAK in patients with wet AMD. Both studies are
actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of extended durability
and targeting multiple disease biologies for differentiated
efficacy. Phase 1b data for KSI-501
was presented in February 2024, and the Phase 3 DAYBREAK study
of KSI-501 in wet AMD is actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6,
VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the
treatment of retinal inflammatory diseases, as currently there are
no available intravitreal biologic therapies addressing the
spectrum of inflammatory conditions of the retina. The Phase
1b APEX study of KSI-101 is actively
enrolling patients, as a precursor to activating the Phase 3 PEAK
and PINNACLE Phase 2b/3 studies in
patients with macular edema secondary to inflammation (MESI).
Kodiak is expanding its research pipeline of duet and triplet
inhibitors that embed small molecules and other active
pharmaceutical ingredients ("APIs") into Kodiak's proprietary
biopolymer backbone to enable high drug-antibody-ratio ("DAR")
medicines. The diverse APIs are designed to be released over time
to achieve targeted, multi-specific and tailored modulation of
biological pathways. The unique combination of high DAR and
tailored therapeutic benefit offers potential for broad application
to multifactorial diseases and builds directly from our Antibody
Biopolymer Conjugate technology and its 15 years of design,
development and manufacturing experience.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak
Sciences Inc. in various global jurisdictions.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding: the
expected benefits of the enhanced formulation for tarcocimab and
KSI-501; the progress and anticipated benefits of our duet and
triplet programs and our ABCD Platform; the prospects and potential
benefits of the product candidates in our pipeline, including
tarcocimab, KSI-501, and KSI-101; the ability of KSI-501 to inhibit
both IL-6 mediated inflammation and VEGF-mediated angiogenesis and
vascular permeability; and the potential success of our ongoing
studies. Forward-looking statements generally include statements
that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as "may," "will,"
"should," "would," "could," "expect," "plan," "believe," "intend,"
"pursue," and other similar expressions among others. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. The risks and uncertainties include,
but are not limited to: the risk that cessation or delay of any of
the on-going clinical studies and our development of tarcocimab,
KSI-501 or KSI-101 may occur; the risk the results of our ongoing
studies may not provide the evidence, insights, or benefits as
anticipated; the risk that safety, efficacy, and durability data
observed in our product candidates in current or prior studies may
not continue or persist; the risk that the results of the
tarcocimab Phase 3 studies may be insufficient to support
regulatory submissions or approval; the risk that a new formulation
of tarcocimab, KSI-501 or other ABC Platform derived molecules may
not provide the benefits expected; the risk that our research and
development efforts and our ability to advance our product
candidates into later stages of development may fail; the risk that
KSI-501 may not inhibit VEGF and IL-6 or have an impact on the
treatment of patients as expected; any one or more of our product
candidates may not be successfully developed, approved or
commercialized; adverse conditions in the general domestic and
global economic markets, which may significantly impact our
business and operations, including our clinical trial sites, as
well as the business or operations of our manufacturers, contract
research organizations or other third parties with whom we conduct
business; as well as the other risks Identified in our filings with
the Securities and Exchange Commission. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled "Risk
Factors" in our most recent Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof
and Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements. Kodiak®, Kodiak Sciences®,
ABC™, ABC Platform™, and the Kodiak logo are registered trademarks
or trademarks of Kodiak Sciences Inc. in various global
jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-host-investor-rd-day-on-september-23-2024-in-new-york-city-302250906.html
SOURCE Kodiak Sciences Inc.